Weight gain Regaining weight is one side effect that people experience when they stop taking a GLP-1
This is a condition related to the digestive system and there has been no reported connection between such medicines and diverticulitis
For many patients, injectable therapy has been an effective option, yet acceptance and long-term adherence can be limited by concerns related to injections
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Its not for everyone
Supplementary information Slideset of figures (download PPTX (PPTX 756 kb) Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
